Advertisement

We need your help now

Support from readers like you keeps The Journal open.

You are visiting us because we have something you value. Independent, unbiased news that tells the truth. Advertising revenue goes some way to support our mission, but this year it has not been enough.

If you've seen value in our reporting, please contribute what you can, so we can continue to produce accurate and meaningful journalism. For everyone who needs it.

Shutterstock/SmartPhotoLab
covid jab

A single dose of Astrazeneca Covid-19 vaccine may reduce transmission by two thirds, study says

Ireland expects to receive its first shipment of the newly-approved vaccine next week.

A SINGLE DOSE of the Astrazeneca vaccine may reduce transmission of coronavirus by two thirds, according to a new study which provides a major boost to the UK’s recommendation that the second jab should be delayed for up to 12 weeks.

Researchers said that the first dose of the Oxford/AstraZeneca jab offers protection of 76% up to three months and may reduce transmission by 67% – with efficacy rising to 82.4% after the second dose 12 weeks later.

The data from the study by the University of Oxford, which has not yet been peer reviewed, supports the four to 12-week prime-boost dosing interval that many global regulators, including the UK’s, have recommended.

Before these results, little was known about how effective the Covid-19 vaccines were at preventing transmission of the disease.

The findings indicate that those who have been vaccinated are not only protected from the disease, but that they are not likely to pass on the virus to anyone.

It also suggests the vaccine eliminates severe illness, as none of those in the study were admitted to hospital with coronavirus.

British Health Secretary Matt Hancock said: “This is a hugely encouraging study and further reinforces our confidence that vaccines are capable of reducing transmission and protecting people from this awful disease.

“This report shows the Oxford vaccine works and works well.”

Prime Minister Boris Johnson said the data from the study was “really encouraging”.

Professor Andrew Pollard, chief investigator of the Oxford Vaccine Trial – and study co-author, said: “These new data provide an important verification of the interim data that was used by more than 25 regulators including the MHRA (Medicines and Healthcare products Regulatory Agency) and EMA (European Medicines Agency) to grant the vaccine emergency use authorisation.

“It also supports the policy recommendation made by the Joint Committee on Vaccination and Immunisation (JCVI) for a 12-week prime-boost interval, as they look for the optimal approach to roll out, and reassures us that people are protected from 22 days after a single dose of the vaccine.”

A former chair at the Faculty of Pharmaceutical Medicine, Dr Gillies O’Bryan-Tear, said the results were the first definitive estimate of the impact of vaccination on transmission rates.

“If the effect on transmission is confirmed for the Pfizer vaccine too, this would be very positive,” he said.

Minister for Health Stephen Donnelly said yesterday that 35,000 doses of the Oxford-AstraZeneca vaccine are due to be delivered to Ireland next week.

Your Voice
Readers Comments
30
This is YOUR comments community. Stay civil, stay constructive, stay on topic. Please familiarise yourself with our comments policy here before taking part.
Leave a Comment
    Submit a report
    Please help us understand how this comment violates our community guidelines.
    Thank you for the feedback
    Your feedback has been sent to our team for review.

    Leave a commentcancel